Overview:
Human epidermal growth factor receptor 2 (HER2) mutations represent a distinct and increasingly recognized oncogenic driver in non-small cell lung cancer (NSCLC). While HER2 has long been a therapeutic target in breast and gastric cancers, recent advances in molecular testing and targeted therapy development are expanding treatment options for patients with HER2-altered NSCLC. Until recently, treatment for these patients was limited, with conventional chemotherapy and non-selective HER2 inhibitors offering suboptimal outcomes.
This live webinar provides oncology clinicians with expert insights into the latest clinical data and therapeutic mechanisms of emerging HER2-targeted TKIs, including zongertinib and BAY 2927088. It also addresses key considerations for patient selection, biomarker testing, and adverse event management to support the effective integration of these agents into NSCLC treatment strategies.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Evaluate the clinical efficacy and safety profiles of emerging HER2-targeted TKIs in patients with non-small cell lung cancer (NSCLC).
- Identify appropriate patient populations for treatment with novel HER2-targeted TKIs
Eric K. Singhi, MD
Thoracic Medical Oncologist
Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, TX
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.